Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In the double-blind, placebo-controlled Phase II TPI-H-221 trial in about 260 patients with recurrent herpes
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury